Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

524 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis.
Chaudagar K, Hieromnimon HM, Kelley A, Labadie B, Shafran J, Rameshbabu S, Drovetsky C, Bynoe K, Solanki A, Markiewicz E, Fan X, Loda M, Patnaik A. Chaudagar K, et al. Among authors: patnaik a. bioRxiv [Preprint]. 2023 May 23:2023.05.23.540590. doi: 10.1101/2023.05.23.540590. bioRxiv. 2023. PMID: 37292972 Free PMC article. Updated. Preprint.
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
González-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu XS, Epping MT, Papa A, Hobbs RM, Chen M, Lunardi A, Ng C, Webster KA, Signoretti S, Loda M, Asara JM, Nardella C, Clohessy JG, Cantley LC, Pandolfi PP. González-Billalabeitia E, et al. Among authors: patnaik a. Cancer Discov. 2014 Aug;4(8):896-904. doi: 10.1158/2159-8290.CD-13-0230. Epub 2014 May 27. Cancer Discov. 2014. PMID: 24866151 Free PMC article.
Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.
Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP. Lunardi A, et al. Among authors: patnaik a. Nat Genet. 2020 Oct;52(10):1132. doi: 10.1038/s41588-020-0701-7. Nat Genet. 2020. PMID: 32884149
Cabozantinib Unlocks Efficient In Vivo Targeted Delivery of Neutrophil-Loaded Nanoparticles into Murine Prostate Tumors.
Chaudagar KK, Landon-Brace N, Solanki A, Hieromnimon HM, Hegermiller E, Li W, Shao Y, Joseph J, Wilkins DJ, Bynoe KM, Li XL, Clohessy JG, Ullas S, Karp JM, Patnaik A. Chaudagar KK, et al. Among authors: patnaik a. Mol Cancer Ther. 2021 Feb;20(2):438-449. doi: 10.1158/1535-7163.MCT-20-0167. Epub 2020 Dec 4. Mol Cancer Ther. 2021. PMID: 33277441
Targeting Innate Immunity in Cancer Therapy.
Rameshbabu S, Labadie BW, Argulian A, Patnaik A. Rameshbabu S, et al. Among authors: patnaik a. Vaccines (Basel). 2021 Feb 9;9(2):138. doi: 10.3390/vaccines9020138. Vaccines (Basel). 2021. PMID: 33572196 Free PMC article. Review.
Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.
Chaudagar K, Hieromnimon HM, Khurana R, Labadie B, Hirz T, Mei S, Hasan R, Shafran J, Kelley A, Apostolov E, Al-Eryani G, Harvey K, Rameshbabu S, Loyd M, Bynoe K, Drovetsky C, Solanki A, Markiewicz E, Zamora M, Fan X, Schürer S, Swarbrick A, Sykes DB, Patnaik A. Chaudagar K, et al. Among authors: patnaik a. Clin Cancer Res. 2023 May 15;29(10):1952-1968. doi: 10.1158/1078-0432.CCR-22-3350. Clin Cancer Res. 2023. PMID: 36862086 Free PMC article.
Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis.
Chaudagar K, Hieromnimon HM, Kelley A, Labadie B, Shafran J, Rameshbabu S, Drovetsky C, Bynoe K, Solanki A, Markiewicz E, Fan X, Loda M, Patnaik A. Chaudagar K, et al. Among authors: patnaik a. Clin Cancer Res. 2023 Dec 1;29(23):4930-4940. doi: 10.1158/1078-0432.CCR-23-1441. Clin Cancer Res. 2023. PMID: 37721526
524 results